There were 449 press releases posted in the last 24 hours and 153,531 in the last 365 days.

Registration Open for 2019 New Frontiers in 3D Conference

Exclusive one-day scientific meeting to discuss practical applications of innovative 3D-cell and organ-on-a-chip technologies to be held April 25, 2019 at MIT

We are witnessing a convergence of new technologies and methodologies that will revolutionize drug discovery.”
— InSphero CSO Dr. Patrick Guye
SCHLIEREN, SWITZERLAND, January 24, 2019 /EINPresswire.com/ -- Registration and abstract submission for the 2019 New Frontiers in 3D Cell Technologies symposium opened today via the conference website. Organized by InSphero AG, a 3D cell culture and organ-on-a-chip pioneer, the conference aims to bring together thought-leaders, research scientists, and regulatory experts actively engaged in pharmaceutical drug discovery and preclinical drug safety testing to discuss innovative trends in 3D cell-based assays and real-world implementation challenges. The conference will feature a keynote presentation by Dr. Matthias von Herrath, Vice President and head of the Novo Nordisk Diabetes R&D Center and Professor at the La Jolla Institute for Immunology.

The one-day scientific meeting, to be held April 25, 2019, at the Massachusetts Institute of Technology in Cambridge, Massachusetts, will include sessions on organ-on-a-chip networks, scalable disease modeling platforms, alternatives to animal testing, and predictive drug safety screening, with invited speakers from AstraZeneca, Takeda Pharmaceuticals, and MIT. Additional speakers will be selected from attendee abstracts submitted for podium presentations, with abstracts for consideration due by March 25, 2019. The registration fee, which includes access to a full day of scientific sessions and discussion, as well as a networking reception and meals, is $299, with an early registration discount available to participants who register before March 25.

InSphero Chief Scientific Officer Dr. Patrick Guye, who helped shaped this year’s conference program and has served on scientific advisory committees for similar conferences and working groups that seek to benefit the broader research community, says, “We are witnessing a convergence of new technologies and methodologies that will revolutionize drug discovery. This New Frontiers in 3D conference offers an international forum to explore how we can effectively harness and apply these emerging technologies, while developing best practices that push the bench closer to the bedside.” The program committee is selecting speakers who are at the forefront of their fields to share their experiences working with organ-on-a-chip systems, scalable 3D cell-based assays, and complex in vitro models that more closely replicate the complexity of healthy and diseased human biology. All participants will be encouraged to voice opinions and actively contribute to the discussion.

To register or learn more about the New Frontiers in 3D conference, visit newfrontiersin3d.com/

For more information about InSphero, visit insphero.com.

Frank Junker, Chief Business Officer
InSphero AG
+41 44 515 04 90
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.